Dysregulated myeloid-T cell immunity in refractory Mycoplasma pneumoniae pneumonia: high inflammation meets T cell

Yanjuan Yu1, Zijie Li2, Gaijing Jia1

  • 1Henan Children's Hospital, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou Children's Hospital, Zhengzhou, 450018, China.

BMC Microbiology
|May 29, 2026
PubMed
Abstract

Insights

Refractory Mycoplasma pneumoniae pneumonia (RMPP) shows immune imbalance with high myeloid activity and low T cell response, impacting the JAK-STAT pathway. This finding offers new insights into RMPP mechanisms and potential treatments.

Area of Science:

  • Immunology
  • Pulmonology
  • Infectious Diseases

Background:

  • Refractory Mycoplasma pneumoniae pneumonia (RMPP) presents a growing clinical challenge.
  • The underlying immunological mechanisms of RMPP are not well understood.

Purpose of the Study:

  • To investigate the cytokine profiles and immunological mechanisms in RMPP.
  • To identify potential biomarkers and therapeutic targets for RMPP.

Main Methods:

  • Analyzed cytokine profiles in bronchoalveolar lavage fluid (BALF) from RMPP, general Mycoplasma pneumoniae pneumonia (GMPP), and bronchial foreign body patients using protein array technology.
  • Utilized protein-protein interaction (PPI) network and pathway enrichment analyses to explore functional interactions of differentially expressed cytokines (DECs).
  • Correlated DECs with clinical indicators and prognostic parameters.

Main Results:

  • Identified seven DECs: T cell-associated (IL-12p70, IFN-γ, IL-7, IL-4) and myeloid-associated (IL-8, MCP-1, MIP-1β).
  • Observed decreased T cell cytokines and elevated myeloid cytokines in RMPP BALF compared to GMPP.
  • Found DECs enriched in the JAK-STAT signaling pathway, with IL-12p70 and IL-4 showing discriminative potential.

Conclusions:

  • RMPP demonstrates dual immune dysregulation: myeloid hyperinflammation and T cell suppression.
  • The dysregulated cytokine network in RMPP converges on the JAK-STAT signaling pathway.
  • These findings provide novel mechanistic insights and suggest potential therapeutic targets for RMPP.

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...